Sign In  |  Register  |  About Los Altos  |  Contact Us

Los Altos, CA
September 01, 2020 1:26pm
7-Day Forecast | Traffic

  • Search Hotels in Los Altos

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Latest News about Eisai Co Ltd

Recent news which mentions Eisai Co Ltd

Biogen tops estimates, raises profit guidance as Alzheimer's drug Leqembi gains traction
Tags Pharmaceuticals Health & Science US: News
From CNBC.com News
5 things to know before the stock market opens Monday
Tags 5 Things to Know Boeing Co Norfolk Southern Corp
From CNBC.com News
Alzheimer's drug Leqembi promises to give patients more time, but they face a long road to treatment
Tags US: News Pharmaceuticals Health & Science
From CNBC.com News
Patients on Alzheimer's drug Leqembi see benefits over three years, Eisai study says
Tags US: News Health & Science Pharmaceuticals
From CNBC.com News
Older GLP-1 drug from Novo Nordisk may slow Alzheimer's disease progression by protecting the brain, study says
Tags Pharmaceuticals Health & Science Eli Lilly and Co
From CNBC.com News
European drug regulator rejects Alzheimer's treatment Leqembi from Biogen, Eisai
Tags US: News Eli Lilly and Co Pharmaceuticals
From CNBC.com News
Jim Cramer says Eli Lilly isn't a 'one trick pony' after FDA advisers endorse its Alzheimer's drug
Tags Investment Strategy Investment strategy Biogen Inc
From CNBC.com News
Biogen tops quarterly profit estimates as cost cuts take hold, Leqembi launch picks up
Tags Biotech and Pharmaceuticals Biotechnology Business News
From CNBC.com News
Eli Lilly says FDA delays approval of Alzheimer's drug in surprise move
Tags US: News Eli Lilly and Co Health & Science
From CNBC.com News
Healthy Returns: The launch of breakthrough Alzheimer’s drug Leqembi is off to a slow start
Tags Biotech and Pharmaceuticals Eisai Co Ltd Science
From CNBC.com News
Biogen revenue and profit shrink on Aduhelm costs, slumping sales of multiple sclerosis therapies
Tags US: News Earnings Health & Science
From CNBC.com News
Biogen drops controversial Alzheimer's drug Aduhelm to focus on Leqembi, experimental treatments
Tags US: News Social issues Health & Science
From CNBC.com News
Weight loss drugs, Alzheimer's treatments and gene editing: Enormous firsts defined 2023 in pharma
Tags Biotech and Pharmaceuticals Biotechnology Business News
From CNBC.com News
Pfizer's twice-daily weight loss pill joins a long list of obesity drug flops
Tags Eli Lilly and Co US: News Novo Nordisk A/S
From CNBC.com News
More convenient form of breakthrough Alzheimer's drug Leqembi shows promising results in study
Tags Science Business News Eisai Co Ltd
From CNBC.com News
5 things to know before the stock market opens Tuesday
Tags Economy Meta Platforms Inc Bank of America Corp
From CNBC.com News
Eli Lilly expects FDA decision on Alzheimer's treatment donanemab by the end of the year
Tags Eli Lilly and Co US: News Pharmaceuticals
From CNBC.com News
Medicare will pay for Alzheimer's drug Leqembi. What patients and doctors should know
Tags Eisai Co Ltd Science Business News
From CNBC.com News
Sales of Alzheimer’s drug Leqembi may be slow initially but could pick up in 2024
Tags Pharmaceuticals Health & Science Law and Regulation
From CNBC.com News
Stocks making the biggest moves midday: Rivian, Levi Strauss, Biogen, First Solar and more
Tags Meta Platforms Inc Breaking News: Markets Economy
From CNBC.com News
Japanese pharma Eisai slides 4% despite FDA approval for Alzheimer's drug
Tags Asia Markets Pharmaceuticals Biogen Inc
From CNBC.com News
FDA approves Alzheimer’s drug Leqembi, paving way for broader Medicare coverage
Tags Business News Science Eisai Co Ltd
From CNBC.com News
FDA advisors to weigh whether Alzheimer's drug Leqembi should receive full approval
Tags Health care industry Pandemics Business
From CNBC.com News
Bernie Sanders says price of Alzheimer's treatment is unconscionable, calls on HHS to take action
Tags US: News Social issues US Economy
From CNBC.com News
Alzheimer's treatment Leqembi could cost Medicare up to $5 billion per year, study estimates
Tags Health & Science Policy Politics
From CNBC.com News
Bipartisan attorneys general call on Medicare to cover Alzheimer's treatments
Tags US: News US Economy Policy
From CNBC.com News
Alzheimer’s patients may wait years to get treated with new drugs, putting them at risk of more severe disease
Tags US Top News and Analysis Policy Disease outbreaks
From CNBC.com News
Alzheimer's: Medicare will cover Leqembi for all patients if FDA approves drug, CMS chief says
Tags Social issues US: News Politics
From CNBC.com News
Biogen isn't concerned about competing with Eli Lilly in the Alzheimer’s drug space, CEO says
Tags Health & Science Pharmaceuticals US: News
From CNBC.com News
Alzheimer’s patients retain the benefits of Leqembi even when they stop the drug, Eisai says
Tags Eisai Co Ltd Science Breaking News: Business
From CNBC.com News
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 LosAltos.com & California Media Partners, LLC. All rights reserved.